Stoke Therapeutics (STOK) Profit After Tax (2018 - 2026)

Stoke Therapeutics' Profit After Tax history runs 9 years deep, the most recent figure standing at -$50.0 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 144.28% year-over-year to -$50.0 million; the TTM figure through Mar 2026 stood at -$170.0 million (down 437.87% YoY), while the FY2025 annual figure was -$6.9 million, up 92.26% from the prior year.
• Profit After Tax for Q1 2026 stood at -$50.0 million, up from -$58.5 million in the prior quarter.
• The five-year high for Profit After Tax was $112.9 million in Q1 2025, with the low at -$58.5 million in Q4 2025.
• The 5-year median for Profit After Tax is -$25.7 million (2024), against an average of -$20.7 million.
• Peak annual rise in Profit After Tax reached 528.17% in 2025, while the deepest fall reached 458.4% in 2025.
• Stoke Therapeutics' Profit After Tax stood at -$25.7 million in 2022, then fell by 4.6% to -$26.8 million in 2023, then surged by 60.94% to -$10.5 million in 2024, then tumbled by 458.4% to -$58.5 million in 2025, then rose by 14.57% to -$50.0 million in 2026.
• Business Quant data shows STOK's Profit After Tax at -$50.0 million in Q1 2026, -$58.5 million in Q4 2025, and -$38.0 million in Q3 2025.